Febrile neutropenia in children treated for malignancy

Area of Science:

• Pediatric Oncology
• Infectious Diseases
• Hematology

Background:

• Febrile neutropenia (FN) is a common, life-threatening complication of chemotherapy in children with cancer.
• Bloodstream infections (BSI) account for 10-20% of FN episodes, increasing the risk of multi-drug resistant (MDR) infections.
• Invasive fungal infections (IFI), particularly Aspergillus spp., are increasingly recognized in FN.

Purpose of the Study:

• To review current strategies for managing FN in pediatric cancer patients.
• To highlight the role of infection prevention, antimicrobial stewardship, and novel diagnostics.
• To discuss the development and future of clinical decision rules (CDR) for FN risk assessment.

Main Methods:

• Review of literature on FN management, infection prevention, diagnostics, and CDRs in pediatric oncology.
• Analysis of emerging pathogens in BSI and IFI associated with FN.
• Evaluation of diagnostic tools like multiplex PCR and their impact on targeted therapy.

Main Results:

• Robust infection prevention (e.g., CVL care bundles) and antimicrobial stewardship can reduce BSI and MDR infections.
• Novel diagnostics (e.g., multiplex PCR) enable early and targeted treatment, reducing unnecessary antimicrobial exposure.
• Validated CDRs exist for specific pediatric populations, aiding risk stratification.

Conclusions:

• Improved infection control, diagnostics, and risk assessment are crucial for managing FN in pediatric cancer patients.
• Further research is needed to develop a universal CDR for standardized FN management.
• Optimizing FN care can lead to reduced complications, outpatient treatment possibilities, and better patient outcomes.